Publications by authors named "E Lopez Gallardo"

Volumetric absorptive microsampling (VAMS) is an emerging technique in clinical and forensic toxicology. It is recognized as a promising alternative to traditional sampling methods, offering an accurate and minimally invasive means of collecting small volumes of biological samples, such as blood, urine, and saliva. Unlike conventional methods, VAMS provides advantages in terms of sample stability, storage, and transportation, as it enables samples to be collected outside laboratory environments without requiring refrigeration.

View Article and Find Full Text PDF

Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases. However, the data supporting these recommendations were generated before androgen receptor pathway inhibitors (ARPIs) were available.

View Article and Find Full Text PDF

Aims: Sarcoendoplasmic reticulum Ca-ATPase 2 (SERCA2), encoded by ATP2A2, is a key protein involved in intracellular Ca homeostasis. The SERCA2a isoform is predominantly expressed in cardiomyocytes and type I myofibres. Variants in this gene are related to Darier disease, an autosomal dominant dermatologic disorder, but have never been linked to myopathy.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE.

Patients And Methods: This was a non-interventional, multicenter, observational, prospective study carried out in 62 Oncology and Hematology services in Spain and Portugal between January 2018 and December 2019.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on long-term outcomes and healthcare resource utilization in patients with generalized myasthenia gravis (gMG).
  • About 220 patients were analyzed over eight years, showing significant improvement in daily living scores and a reduction in healthcare costs, although some patients continued to experience symptoms and drug-related adverse events.
  • The findings suggest that while most patients experience positive outcomes, a minority still suffer from persistent symptoms and side effects, highlighting the ongoing burden of gMG on both patients and healthcare systems.
View Article and Find Full Text PDF